Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.

Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.

Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.

Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.

Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.

Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.

Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.

Abstract: A method of diagnosing a cooling subsystem of an engine system in response a parameter extracted from dynamic hydraulic pressure sensed in the cooling subsystem, and products and systems using same.

Abstract: A method of diagnosing a cooling subsystem of an engine system in response a parameter extracted from dynamic hydraulic pressure sensed in the cooling subsystem, and products and systems using same.

Abstract: An air filter system with an air filter element having an inflow and an outflow face and comprising alternating flat and pleated layers, which are configured to form channels. The channels are alternately sealed in inflow and outflow direction, such that the medium to be filtered must pass through one of the layers as it flows from the inflow face through the filter to the outflow face. An adsorber element made of an activated carbon coated honeycomb structure is disposed adjacent the air filter element.

Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.

Abstract: The present invention relates to the use of Parapoxviruses in combination with other agents for the treatment of viral diseases, and in particular HIV infections and AIDS. The invention also relates to methods for producing medicaments based on combinations of Parapoxviruses and other antiviral agents, and to such medicaments. In particular, the invention relates to the use of Parapoxviruses in combination with agents of the kind used for antiretroviral therapy and highly active antiretroviral therapy (HAART).

Abstract: A method includes sensing pressure within an engine cylinder, and estimating at least one other engine system parameter based on the sensed pressure. Another method includes designing an engine system, which includes one or more engine cylinder pressure sensors and one or more other engine system sensors. According to this method, the engine system is operated, and engine cylinder pressure is sensed using the engine cylinder pressure sensors, which are in communication with an engine cylinder of an engine of the engine system. Also, other engine system parameters are sensed to obtain at least one other engine system parameter using the other engine system sensors. The engine cylinder pressure is correlated to the at least one other engine system parameter, and engine cylinder pressure is used to replace or augment the at least one other engine system parameter that correlates to the engine cylinder pressure.

Abstract: The present invention relates to substituted chromanol derivatives, to processes for their preparation, to their use on their own or in combination for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.

Abstract: The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the treatment and/or prevention of cardiovascular disorders, in particular hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias and arteriosclerosis.

Abstract: An air management assembly (10) for use in an engine (12) with an exhaust manifold (14) that outputs an exhaust gas and an intake manifold (16), with a filter (18) in fluid communication between the exhaust manifold (14) and turbocharger (20). The air management assembly (10) provides a compressor (22), a turbine (24), at least one gaseous fluid cooler (32, 36, 44), at least one bypass (28, 28)? and a housing (30) where the compressor (22), turbine (24), at least one gaseous fluid cooler (32), (36, 44), bypass (28, 28?), or combination thereof are integrated into the housing (30). The compressor (22) is in fluid communication with the intake manifold (16). The turbine (24) is in fluid communication with the exhaust manifold (14). The turbine (24) and the compressor (22) are moveably coupled and move in conjunction with one another. The gaseous fluid coolers (32, 36, 44) are in fluid communication with the compressor (32), turbine (24), or combination thereof.

Abstract: The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the treatment and/or prevention of cardiovascular disorders, in particular hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias and arteriosclerosis.

Abstract: The present invention relates to a compressor-cooler module, having a housing, a compressor contained in the housing, and an air cooler disposed within the housing and positioned in the flow path of the compressor. The present invention also includes an intake in fluid communication with the housing, a cooler bypass valve operably associated with the air cooler and the compressor, and a low-pressure exhaust gas recirculation passage operably associated with the cooler bypass valve, and the cooler bypass valve selectively directs exhaust gas to bypass the air cooler.

Abstract: The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused by virus infections comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.

Abstract: The present invention is an exhaust gas recirculation system for a motor vehicle, having a turbocharger unit (18) which has a turbine (20) and a compressor (36), the compressor (36) having a compressor wheel (42) which rotates on an axis (66). There is also a dispersion apparatus (56) operably associated with a condensation separation apparatus (58). The condensation separation apparatus (58) separates moisture from exhaust gas flowing from the turbine (20), and the dispersion apparatus (56) reintroduces the moisture into the compressor (36) in proximity to the compressor wheel axis (66), preventing erosion of the compressor wheel (42).